Affiliations: [a] INSERM, UMR1231, Labex LipSTIC, Dijon, France
| [b] Université de Bourgogne-Franche Comté, Dijon, France
| [c] Department of Neurology and Laboratory of Neurobiology, Hospital Clinico San Carlos, Health Research Institute “San Carlos” (IdISCC), Universidad Complutense de Madrid, Madrid, Spain
| [d]
Cancer Centre Georges François Leclerc, Dijon, France
| [e] Department of Nuclear Medicine. Hospital Clinico San Carlos, Health Research Institute “San Carlos” (IdISCC), Universidad Complutense de Madrid, Madrid, Spain
Correspondence:
[*]
Correspondence to: Jordi A. Matías-Guiu, Department of Neurology, Hospital Clinico San Carlos, Health Research Institute “San Carlos” (IdISCC), Universidad Complutense de Madrid, Prof. Martin Lagos s/n. 28040, Madrid, Spain. Tel.: +34913303511; +34676933312; E-mails: jordimatiasguiu@hotmail.com and jordi.matias-guiu@salud.madrid.org.
Note: [1] These authors contributed equally to this work.
Abstract: We aimed to study the expression of circulating heat-shock protein HSP70 and exosomes in plasma of a cohort of patients with Alzheimer’s disease (AD) and frontotemporal dementia (FTD) at different stages. We performed correlations with clinical scales and FDG-PET. HSP70 levels were higher within exosomes than free in plasma. Moderate correlations were found between exosomal HSP70 and CDR, FTLD-CDR, and extension of hypometabolism. Our results suggest modifications in the level of exosomal HSP70 during the course of neurodegeneration, regardless of AD or FTD, and therefore HSP70 could have a potential role in the follow-up of these disorders.
Keywords: Alzheimer’s disease, biomarkers, exosomes, frontotemporal dementia, PET
